We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01024231
Recruitment Status : Active, not recruiting
First Posted : December 2, 2009
Last Update Posted : December 13, 2017
Ono Pharma USA Inc
Information provided by (Responsible Party):
Bristol-Myers Squibb